July 14, 2011 (Prague, Czech Republic) — Paricalcitol was superior to cinacalcet in achieving target parathyroid hormone (PTH) levels in patients with secondary hyperparathyroidism (SHPT), a ...
Review the side-effects of Paricalcitol as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...
PRAGUE—Paricalcitol is superior to cinacalcet in achieving target parathyroid hormone levels in patients with secondary hyperparathyroidism (SHPT), data show. Either a vitamin D receptor activator ...
Please provide your email address to receive an email when new articles are posted on . Adding 2 mcg per day of paricalcitol to renin-angiotension-aldosterone system inhibition appears to be a novel ...
July 30, 2003 — Paricalcitol, an intravenous vitamin D formulation, may improve survival in patients on hemodialysis compared with calcitriol, according to the results of a historical cohort study ...
Meta-analysis shows comparable efficacy in lowering iPTH, but analyses of patient-centered outcomes such as mortality and cardiovascular death were not possible. A new systematic review and ...
Please provide your email address to receive an email when new articles are posted on . Patients with type 2 diabetes and macroalbuminuria prescribed the antihypertensive drug losartan saw an enhanced ...
INTRODUCTION Secondary hyperparathyroidism (SHPT) is a common hormonal disorder associated with chronic kidney disease (CKD). The treatment of SHPT should lead to a reduction in parathormone ...
Neoadjuvant gemcitabine, docetaxel, and capecitabine results in comparable surgical outcomes to modified FOLFIRINOX in patients with pancreatic ductal adenocarcinoma who also receive radiation: A ...
Elevated calcium and phosphorus levels after therapy with injectable vitamin D for secondary hyperparathyroidism may accelerate vascular disease and hasten death in patients undergoing long-term ...
The efficacy and safety of calculating initial paricalcitol dose for patients with secondary hyperparathyroidism (SHPT) from the baseline intact parathyroid hormone (iPTH) level (i.e. disease severity ...
Marksans Pharma has received approval from the US health regulator for Paricalcitol capsules, used for treating hyper parathyroidism. "USFDA (US Food & Drug Administration) has granted approval for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results